Proactive - Interviews for investors

Regan Capital CIO Skyler Weinand joined Steve Darling from Proactive to share news about the dynamics of the fixed income markets, interest rates, and mortgage-backed securities. Weinand outlined Regan Capital’s focus on U.S. mortgage-backed securities, noting the company manages around $3.6 billion across mutual funds, ETFs, and a UCITS ETF for non-U.S. investors. “Mortgages are about $13.5 trillion outstanding,” Weinand said, emphasizing the scale of the U.S. mortgage market and the challenges retail investors face accessing it directly. He discussed how recent Federal Reserve rate cuts have not lowered long-term interest rates. In fact, the yield on longer-term bonds and mortgage rates have increased. Weinand stated, “Mortgage rates are actually higher today than they were last September.” He cautioned that loose financial conditions, robust corporate balance sheets, and rising equity markets suggest rates could move higher, even if the Fed implements more cuts. He noted growing corporate debt issuance, with examples like Google’s 50-year bond at a 5.7% coupon. For investors, Weinand recommended focusing on short-duration and floating-rate securities, especially those backed by U.S. government guarantees, which can offer higher yields with lower volatility. #FixedIncome #InterestRates #MortgageBonds #SkylerWeinand #ReganCapital #BondMarket #ETFs #ShortDurationBonds #FederalReserve #FinancialMarkets #InvestmentStrategy #FloatingRate #ProactiveInvestors

Standard Uranium CEO Jon Bey joined Steve Darling from Proactive to discuss the company’s operational progress throughout 2025 and outline its strategic roadmap heading into 2026, highlighting a year marked by successful capital raising, advancing exploration programs, and the expansion of its joint venture portfolio. Bey noted that Standard Uranium raised nearly C$7.0 million during 2025, providing the financial foundation to advance multiple exploration initiatives across its project portfolio. A significant portion of that capital has been allocated to the Davidson River project, which is now fully funded and preparing for the largest drill program in the project’s history. Drilling at Davidson River is scheduled to begin in late May 2026 and is expected to be a major catalyst for the company. One of the year’s key developments was the return of 100% ownership of the Sun Dog project to Standard Uranium after joint venture partner Arrow Energy was unable to meet its funding commitments. Bey explained that this outcome has positioned the company to re-engage the market, confirming that multiple confidentiality agreements have already been signed with interested joint venture partners. Subject to final agreements, drilling at Sun Dog is expected to resume in late summer 2026. The company also continued to advance its project generator business model by securing new joint venture agreements. Standard Uranium entered into a partnership with Aventis on the Corvo project and a separate agreement with Collective Metals on the Rocas project. Both projects are on track to begin drilling in the first quarter of 2026, further diversifying the company’s near-term exploration pipeline. Looking ahead, Bey confirmed that Standard Uranium’s full management and technical team will attend the Vancouver Resource Investment Conference in January 2026. The company plans to meet with investors and stakeholders at the event to provide updates on its exploration plans and outline anticipated catalysts for the year ahead. #proactiveinvestors #standarduraniumltd #tsxv #stnd #otcqb #sttdf #mining #uranium #corvoproject #UraniumExploration #AthabascaBasin #DavidsonRiver #MiningInnovation #Geophysics #AmbientNoiseTomography #ResourceInvesting #FleetSpace #UraniumDiscovery #MiningNews

1911 Gold Corporation Chairman Gary O’Connor joined Steve Darling from Proactive to announce the start of a 2,200-metre diamond drilling program at the Ogama-Rockland gold deposit, located southeast of the company’s True North Gold Project. The program has already commenced, with one surface diamond drill rig mobilized to site. The drilling campaign is designed to support both resource expansion and confirmation, as the company continues to advance its understanding of the Ogama-Rockland deposit and its potential integration with existing infrastructure at True North. The Ogama-Rockland gold deposit currently hosts an NI 43-101 compliant inferred mineral resource of approximately 1.28 million tonnes grading 8.17 grams per tonne gold, containing an estimated 337,000 ounces of gold. O’Connor emphasized that the deposit’s high-grade nature and shallow mineralization make it an attractive near-term development opportunity. According to O’Connor, the planned eight drill holes will focus on confirming the updated geological model and testing extensions of high-grade, quartz-vein-hosted gold mineralization at relatively shallow depths. Drilling will target both down-dip and along-strike extensions of the main vein system, as well as newly identified parallel structures that emerged from recent relogging and resampling of historical drill core and updated geological modelling. In addition to expanding the resource base, the company plans to conduct metallurgical test work on drill core samples collected during the program. This testing will evaluate the suitability of processing material from Ogama-Rockland at the existing True North processing facility, potentially providing a streamlined development pathway and capital efficiencies. Following completion of the drill program and analysis of the results, 1911 Gold plans to deliver an updated underground mineral resource estimate in the first half of 2026. The company views this program as an important step in unlocking additional value at Ogama-Rockland while leveraging its established infrastructure at the broader True North project. #proactiveinvestors #1911goldcorporation #1911gold #tsxv #aumb #otcqx #aumbf #GoldExploration #MiningNews #TrueNorthGold #OgamaRockland #DrillingUpdate #PEA #ResourceUpdate #GoldMiningCanada #TSXV #JuniorMining

BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company’s recent progress across its two lead drug candidates, Bezisterim and BIV201, as BioVie positions itself for multiple clinical and regulatory catalysts in 2026. Bezisterim, an anti-inflammatory compound that blocks tumor necrosis factor alpha (TNF-α), is being evaluated across several indications, including Parkinson’s disease, long COVID, and Alzheimer’s disease. Do highlighted that the compound has delivered encouraging signals in prior studies, including improvements in muscle control and cognitive function, as well as evidence suggesting a slowing of biological aging. Building on these results, BioVie has launched a new clinical trial enrolling 60 patients with earlier-stage Parkinson’s disease to evaluate Bezisterim as a standalone therapy. The goal of the study is to assess the drug’s potential disease-modifying effects when administered earlier in the disease course. Topline data from this trial are expected in April or May of 2026. In parallel, BioVie is advancing a separate, larger clinical program targeting long COVID. The company is conducting a 200-patient trial designed to evaluate Bezisterim’s ability to address persistent inflammatory mechanisms believed to drive many long COVID symptoms. Enrollment for this study is expected to be completed by February 2026. The trial is supported by a $13 million grant awarded to BioVie, underscoring the growing recognition of inflammation as a key contributor to long COVID. Do also provided an update on BioVie’s second lead candidate, BIV201, which is being developed to treat ascites associated with late-stage liver disease. The company’s Phase 2 trial of BIV201 was stopped early after interim data showed the drug reduced fluid accumulation by more than 50%, a clinically meaningful outcome in a difficult-to-treat patient population. Following discussions with the U.S. Food and Drug Administration, BioVie has now received feedback and authorization to advance BIV201 directly into a single Phase 3 clinical trial, streamlining the development pathway. Looking ahead, Do emphasized that BioVie expects 2026 to be a transformational year, with multiple clinical data readouts across programs and the potential initiation of a pivotal Phase 3 study. “2026 will be a big catalyst year for us,” he said, highlighting the breadth of opportunities across the company’s pipeline. proactiveinvestors #biovieince #nasdaq #bivi #alzheimersdisease #dementia #Alzheimers #Dementia #NeurodegenerativeDiseases #BrainHealth #BioVie #CognitionImprovement #Neuroinflammation #SocialImpact #DementiaAwareness #ElderlyCare #Neuroscience #MemoryImprovement #AlzheimersResearch #HealthCrisis #DementiaSupport #BrainScience #GlobalHealth #AlzheimersSolution #Caregivers #HealthyAging #MentalHealth #MedicalResearch #DementiaPrevention #Neurology #WorldAlzheimersDay #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce a key clinical milestone, confirming that the first patient has been successfully dosed with intranasal foralumab in the company’s Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease (AD). This achievement follows the company’s December 12, 2025 announcement that patient enrollment had begun, with first dosing expected imminently. The rapid progression from enrollment to dosing highlights strong site readiness and momentum for the study. The Phase 2 trial is designed to evaluate intranasal foralumab both as a standalone therapy and in combination with FDA-approved anti-amyloid treatments, including lecanemab (Leqembi®) and donanemab. By exploring combination therapy alongside monotherapy, Tiziana aims to assess whether targeting neuroinflammation can provide additive or complementary benefits to existing amyloid-reducing approaches. Elrifi explained that the trial is supported by compelling TSPO-PET imaging data, which demonstrate persistent and widespread microglial activation—a key marker of neuroinflammation—in patients with Alzheimer’s disease. Notably, this neuroinflammatory activity has been shown to persist even after amyloid plaque reduction with therapies such as lecanemab. According to Elrifi, this evidence highlights a critical unmet need in Alzheimer’s treatment: addressing residual neuroinflammation that may continue to drive disease progression. Intranasal foralumab is designed to modulate immune responses within the central nervous system and calm overactivated microglia, potentially reducing chronic inflammation associated with neurodegeneration. The intranasal delivery method is intended to provide targeted central nervous system exposure while minimizing systemic side effects. The Phase 2 study is a randomized, placebo-controlled trial assessing the safety, tolerability, and potential efficacy of intranasal foralumab in patients with early or mild Alzheimer’s disease. Primary endpoints include changes in neuroinflammation as measured by TSPO-PET imaging, cognitive function outcomes, and biomarker changes related to amyloid and tau pathology. With the first patient now dosed, Tiziana Life Sciences advances into the next phase of clinical evaluation, positioning the company to generate meaningful data on whether addressing neuroinflammation—alone or in combination with anti-amyloid therapies—can improve outcomes for patients with early Alzheimer’s disease. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #AlzheimersResearch #Neuroinflammation #BiotechNews #PETscan #ClinicalTrials #AlzheimersTreatment #PharmaUpdates #HealthcareInnovation